DV
Dividend Vision

BLFS Stock — BioLife Solutions, Inc.

Renamed. The figures below are frozen at this symbol's final trading day. Now trading as RGEN.

BioLife Solutions, Inc. (BLFS)

Updated October 5, 2026.

BioLife Solutions develops and manufactures specialized biopreservation media, bioproduction products, and automated processing equipment for the cell and gene therapy industry, serving research and commercial manufacturing customers globally. The company does not currently have an established regular distribution schedule. This equity security may appeal to investors seeking exposure to the cell and gene therapy sector without an expectation of dividend income. BioLife Solutions was acquired by Repligen on October 6, 2026, with each share converted into $11.25 in cash plus 0.1442 Repligen shares, and its stock was delisted from Nasdaq; see RGEN for the acquirer.

BLFS key facts

Asset type
Stock
Asset class
Equity
Inception date
11/22/1989
Distribution frequency
None
Last close
$38.61 (stale; as of 2026-10-05)
Market cap
$1,888,929,920
Average volume
1,164,074
Beta
1.824
Payout ratio
0.0%
P/E ratio
39.00
Forward P/E
117.00
EPS
$0.99

DividendVision analysis is generated from public SEC filing data and may not capture every change. Review the original filing for complete information.